|
0
|
|
Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition.
(nature.com)
|
Pan Y
…
Karlsson MCI
Nature Communications
2026-07-27
|
#cancer
#immunotherapy
#macrophage
#tlr
#amr
|
|
0
|
|
Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.
(linkinghub.elsevier.com)
|
Meyerhoff RR
…
Antonia SJ
Cancer Cell
2026-07-27
|
#antibody
#cancer
#immunotherapy
#immunity
#car-t
|
|
0
|
|
Single-cell RNA-seq and spatial transcriptomics characterize CD8(+) exhausted T cells in pancreatic ductal adenocarcinoma.
(linkinghub.elsevier.com)
|
Mao J
…
Yan Q
iScience
2026-07-27
|
#transcriptomics
#pancreatic cancer
#immunotherapy
#exhaustion
#microenvironment
|
|
0
|
|
The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice.
(nature.com)
|
Kang JM
…
Lim S
Nature Communications
2026-07-27
|
#vaccination
#immunotherapy
#dendritic-cells
#cancer-immunology
#t-cell-immunity
|
|
0
|
|
Tumor-infiltrating plasma cell targets as a source for immunotherapies.
(linkinghub.elsevier.com)
|
Lattanzi G
…
Hollern D
Cancer Cell
2026-07-27
|
#cancer
#immunotherapy
#plasma cells
#car-t
#tumor immunity
|
|
0
|
|
Fangchinoline drives NOS2-dependent host immunity to restrict intracellular enteric pathogens.
(linkinghub.elsevier.com)
|
Sadhu S
…
Awasthi A
iScience
2026-07-27
|
#immunotherapy
#amr
#macrophage
#nitric-oxide
|
|
0
|
|
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.
(nature.com)
|
David S
…
Loi S
Nature Communications
2026-07-27
|
#immunotherapy
#breast cancer
#radiotherapy
#clinical trial
#checkpoint_inhibition
|
|
0
|
|
Host-derived lactic acid disrupts IFN efficacy via antiviral inhibition and proinflammatory amplification.
(nature.com)
|
Tian M
…
Liu Z
Nature Communications
2026-07-27
|
#antiviral
#interferons
#inflammation
#immunotherapy
#viral infection
|
|
0
|
|
Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.
(nature.com)
|
Mahadevan KK
…
Kalluri R
Nature Communications
2026-07-27
|
#immunotherapy
#t cell
#pancreatic cancer
#combination therapy
#checkpoint-blockade
|